Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis.

J Inflamm Res

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland.

Published: February 2013

Bronchiectasis is an airway disease characterized by thickening of the bronchial wall, chronic inflammation , and destruction of affected bronchi. Underlying etiologies include severe pulmonary infection and cystic fibrosis (CF); however, in a substantial number of patients with non-CF-related bronchiectasis (NCFB), no cause is found. The increasing armamentarium of therapies now available to combat disease in CF is in stark contrast to the limited tools employed in NCFB. Our study aimed to evaluate similarities and differences in airway inflammatory markers in patients with NCFB and CF, and to suggest potential common treatment options. The results of this study show that NCFB bronchoalveolar lavage fluid samples possessed significantly increased NE activity and elevated levels of matrix metalloproteinases 2 (MMP-2) and MMP-9 compared to healthy controls (P < 0.01); however, the levels detected were lower than in CF (P < 0.01). Interleukin-8 (IL-8) concentrations were significantly elevated in NCFB and CF compared to controls (P < 0.05), but in contrast, negligible levels of IL-18 were detected in both NCFB and CF. Analogous concentrations of IL-10 and IL-4 measured in NCFB and CF were statistically elevated above the healthy control values (P < 0.05 and P < 0.01, respectively). These results indicate high levels of important proinflammatory markers in both NCFB and CF and support the use of appropriate anti-inflammatory therapies already employed in the treatment of CF bronchiectasis in NCFB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576001PMC
http://dx.doi.org/10.2147/JIR.S40081DOI Listing

Publication Analysis

Top Keywords

ncfb
9
airway inflammatory
8
inflammatory markers
8
cystic fibrosis
8
bronchiectasis ncfb
8
markers individuals
4
individuals cystic
4
fibrosis non-cystic
4
non-cystic fibrosis
4
bronchiectasis
4

Similar Publications

: High-flow nasal therapy (HFNT) has been shown to reduce exacerbations of COPD and some evidence displays benefits in non-cystic fibrosis bronchiectasis (NCFB) patients. The present study aimed to compare the effectiveness of 12 months of home HFNT on the annual exacerbation rate between mild/moderate and severe NCFB patients, classified by the bronchiectasis severity index (BSI). Secondary outcomes were the evaluation of the dyspnea, pulmonary function, and sputum cultures in both groups.

View Article and Find Full Text PDF

The aim of this study was to examine the biological activity and probiotic properties of lactic acid bacteria (LAB) isolated from sweet potato stalk kimchi (SPK). Various LAB and spp. are active in the early stages of the fermentation of kimchi made from sweet potato stalk.

View Article and Find Full Text PDF

Background: Long-term macrolide therapy for non-cystic fibrosis bronchiectasis (NCFB) can play a significant role. However, such data are insufficient regarding the efficacy against severe exacerbation and adverse effects, including the emergence of macrolide-resistant pathogens and prolonged macrolide use beyond 1 year.

Methods: Randomized controlled trials (RCTs) and prospective observational studies comparing the efficacy and safety of macrolides and placebo in adult patients with NCFB were screened on April 10, 2024.

View Article and Find Full Text PDF

Comparative microbiome analysis in cystic fibrosis and non-cystic fibrosis bronchiectasis.

Respir Res

May 2024

Laboratório de Biologia Molecular de Patógenos, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Background: Bronchiectasis is a condition characterized by abnormal and irreversible bronchial dilation resulting from lung tissue damage and can be categorized into two main groups: cystic fibrosis (CF) and non-CF bronchiectasis (NCFB). Both diseases are marked by recurrent infections, inflammatory exacerbations, and lung damage. Given that infections are the primary drivers of disease progression, characterization of the respiratory microbiome can shed light on compositional alterations and susceptibility to antimicrobial drugs in these cases compared to healthy individuals.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to validate a simplified radiological scoring system for evaluating clinical symptoms and outcomes in Taiwanese patients with noncystic fibrosis bronchiectasis (NCFB).
  • It involved analyzing data from 2,753 patients, assessing their bronchiectasis type and severity using a modified Reiff score derived from high-resolution CT scans, and correlating these with clinical features such as lung function and hospitalization rates.
  • The findings indicated that as the severity of bronchiectasis increased, patients experienced worse symptoms and lung function, and identified factors like age and pneumonia as independent predictors of mortality, suggesting the scoring system's utility in clinical assessments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!